Isatis indigotica root polysaccharides as adjuvants for an inactivated rabies virus vaccine

International Journal of Biological Macromolecules

Volumn 87, Issue , 2016, Pages 7-15

  Zhang, Weijiao ^a,b   Zheng, Xuexing ^b   Cheng, Nan ^b   Gai, Weiwei ^a,b   Xue, Xianghong ^b   Wang, Yuxia ^b   Gao, Yuwei ^b   Shan, Junjie ^b   Yang, Songtao ^a,b   Xia, Xianzhu ^b  

^a JILIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Adjuvant; Antibody titer; Cellular immunity; Polysaccharide; Rabies vaccine

Indexed keywords

ALUMINUM HYDROXIDE; GAMMA INTERFERON; INACTIVATED VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; POLYSACCHARIDE; RABIES VACCINE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE ACTIVATION; BLOOD SAMPLING; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; INGUINAL LYMPH NODE; ISATIS; ISATIS INDIGOTICA; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PLANT ROOT; PROTECTION; RABIES; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; VIRUS VIRULENCE; ANIMAL; B LYMPHOCYTE; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; PATHOGENICITY; RABIES VIRUS; SECRETION (PROCESS); SPLEEN; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; B-LYMPHOCYTES; CYTOKINES; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; ISATIS; MICE; MICE, INBRED BALB C; PLANT ROOTS; POLYSACCHARIDES; RABIES VACCINES; RABIES VIRUS; SPLEEN; T-LYMPHOCYTES; VACCINES, INACTIVATED;

EID: 84958538966     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2016.02.023     Document Type: Article

References (47)

1. Dietzschold B., Schnell M., Koprowski H. Pathogenesis of rabies. Curr. Top. Microbiol. Immunol. 2005, 292:45-56.
2. Fu Z.F. Rabies and rabies research: past, present and future. Vaccine 1997, 15(Suppl):S20-S24.
3. Knobel D.L., Cleaveland S., Coleman P.G., Fèvre E.M., Meltzer M.I., Miranda M.E., Shaw A., Zinsstag J., Meslin F.X. Reevaluating the burden of rabies in Africa and Asia. Bull. World Health Organ. 2005, 83:360-368.
4. World Health Organization, WHO Expert Consultation on Rabies, Second Report, World Health Organ. Tech. Rep. Ser., 2013, pp. 1-139 (back cover).
5. Rupprecht C.E. A tale of two worlds: public health management decisions in human rabies prevention. Clin. Infect. Dis. 2004, 39:281-283.
6. Hu R.L., Fooks A.R., Zhang S.F., Liu Y., Zhang F. Inferior rabies vaccine quality and low immunization coverage in dogs (Canis familiaris) in China. Epidemiol. Infect. 2008, 136:1556-1563.
7. Davlin S.L., Vonville H.M. Canine rabies vaccination and domestic dog population characteristics in the developing world: a systematic review. Vaccine 2012, 30:3492-3502.
8. K.M. Charlton, Report of the Meeting Control of Rabies in the Americas, Animal Diseases Research Institute, 11-13 September 1991, Can. Vet. J. 33 (1992) 98-99.
9. Nguyen K.A., Nguyen T.T., Nguyen D.V., Ngo G.C., Nguyen C.N., Yamada K., Noguchi K., Ahmed K., Hoang H.D., Nishizono A. Evaluation of rapid neutralizing antibody detection test against rabies virus in human sera. Trop. Med. Health 2015, 43:111-116.
10. Mittal M.K. Revised 4-dose vaccine schedule as part of postexposure prophylaxis to prevent human rabies. Pediatr. Emerg. Care 2013, 29:1119-1121. (quiz 1122-1114).
11. Ondrejkova A., Suli J., Ondrejka R., Benisek Z., Franka R., Scvrcek S., Madar M., Bugarsky A. Comparison of the detection and quantification of the rabies antibodies in canine sera. Vet. Med. Czech 2002, 47:218-221.
12. Takayama N. Anti-rabies antibody levels observed in subjects who were bitten by supposed rabid animals abroad and received post-exposure immunization. Kansenshogaku Zasshi 1998, 72:1046-1049.
13. Sage G., Khawplod P., Wilde H., Lobaugh C., Hemachudha T., Tepsumethanon W., Lumlertdaecha B. Immune response to rabies vaccine in Alaskan dogs: failure to achieve a consistently protective antibody response. Trans. R. Soc. Trop. Med. Hyg. 1993, 87:593-595.
14. Minke J.M., Bouvet J., Cliquet F., Wasniewski M., Guiot A.L., Lemaitre L., Cariou C., Cozette V., Vergne L., Guigal P.M. Comparison of antibody responses after vaccination with two inactivated rabies vaccines. Vet. Microbiol. 2009, 133:283-286.
15. Van De Zande S., Kaashoek M., Hesselink W., Sutton D., Nell T. Comments to Comparison of antibody responses after vaccination with two inactivated rabies vaccines [Minke, J.M. et al., 2009. Vet. Microbiol. 133, 283-286]. Vet. Microbiol. 2009, 138:202-203.
16. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 2004, 82:497-505.
17. Exley C., Siesjo P., Eriksson H. The immunobiology of aluminium adjuvants: how do they really work?. Trends Immunol. 2010, 31:103-109.
18. Lindblad E.B. Aluminium adjuvants-in retrospect and prospect. Vaccine 2004, 22:3658-3668.
19. Aprile M.A., Wardlaw A.C. Aluminium compounds as adjuvants for vaccines and toxoids in man: a review. Can. J. Public Health 1966, 57:343-360.
20. Lin Haixiang P.P. Influence of aluminum adjuvant to experimental rabies vaccine. Chin. J. Exp. Clin. Virol. 1999, 13:133-136.
21. Liu Y., Zhang S., Zhang F., Hu R. Adjuvant activity of Chinese herbal polysaccharides in inactivated veterinary rabies vaccines. Int. J. Biol. Macromol. 2012, 50:598-602.
22. Su X., Pei Z., Hu S. Ginsenoside Re as an adjuvant to enhance the immune response to the inactivated rabies virus vaccine in mice. Int. Immunopharmacol. 2014, 20:283-289.
23. Wang X.L., Chen M.H., Wang F., Bu P.B., Lin S., Zhu C.G., Li Y.H., Jiang J.D., Shi J.G. Chemical consitituents from root of Isatis indigotica. Zhongguo Zhong Yao Za Zhi 2013, 38:1172-1182.
24. Zuo L., Li J.B., Xu J., Yang J.Z., Zhang D.M., Tong Y.L. Studies on chemical constituents in root of Isatis indigotica. Zhongguo Zhong Yao Za Zhi 2007, 32:688-691.
25. Yang Z., Wang Y., Zheng Z., Zhao S., Zhao J., Lin Q., Li C., Zhu Q., Zhong N. Antiviral activity of Isatis indigotica root-derived clemastanin B against human and avian influenza A and B viruses in vitro. Int. J. Mol. Med. 2013, 31:867-873.
26. Lin C.W., Tsai F.J., Tsai C.H., Lai C.C., Wan L., Ho T.Y., Hsieh C.C., Chao P.D. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antivir. Res. 2005, 68:36-42.
27. Shan J., Sun G., Ren J., Zhu T., Jia P., Qu W., Li Q., Wu J., Ma H., Wen S., Wang Y. An alpha-glucan isolated from root of Isatis Indigotica, its structure and adjuvant activity. Glycoconj. J. 2014, 31:317-326.
28. Shan J., Zhao C., Li Q., Zhu T., Ren J., Li H., Wu J., Ma H., Qu W., Wang Y. An arabinogalactan from Isatis indigotica and its adjuvant effects on H1N1 influenza and hepatitis B antigens. J. Funct. Foods 2015, 18:631-642.
29. Pandey V.K., Shankar B.S., Sainis K.B. G1-4A, an arabinogalactan polysaccharide from Tinospora cordifolia increases dendritic cell immunogenicity in a murine lymphoma model. Int. Immunopharmacol. 2012, 14:641-649.
30. Udani J.K., Singh B.B., Barrett M.L., Singh V.J. Proprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: a randomized, double-blind, placebo-controlled, pilot study in healthy volunteers. Nutr. J. 2010, 9:32.
31. Chintalwar G., Jain A., Sipahimalani A., Banerji A., Sumariwalla P., Ramakrishnan R., Sainis K. An immunologically active arabinogalactan from Tinospora cordifolia. Phytochemistry 1999, 52:1089-1093.
32. Xue X.H., Zheng X.X., Wang H.L., Ma J.Z., Li L., Gai W.W., Wang T.C., Yang S.T., Xia X.Z. An inactivated recombinant rabies CVS-11 virus expressing two copies of the glycoprotein elicits a higher level of neutralizing antibodies and provides better protection in mice. Virus Genes 2014, 48:411-420.
33. Cliquet F., Aubert M., Sagne L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J. Immunol. Methods 1998, 212:79-87.
34. Gozdas H.T. The importance of rabies immunoglobulin in postexposure prophylaxis. Am. J. Emerg. Med. 2015, 33:594.
35. Tarantola A., Ly S., In S., Ong S., Peng Y., Heng N., Buchy P. Rabies vaccine and rabies immunoglobulin in Cambodia: use and obstacles to use. J. Travel Med. 2015, 22:348-352.
36. Jain R.S., Gupta P.K., Handa R., Tejwani S., Prakash S., Kumar S., Agrawal R., Sisodiya M.S. Paralytic rabies or postvaccination myelitis: a diagnostic dilemma. Am. J. Emerg. Med. 2015, 33(601):e601-e603.
37. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J. Immunol. 1999, 163:6448-6454.
38. Brown G.D., Gordon S. Fungal beta-glucans and mammalian immunity. Immunity 2003, 19:311-315.
39. Nair P.K., Melnick S.J., Ramachandran R., Escalon E., Ramachandran C. Mechanism of macrophage activation by (1,4)-alpha-d-glucan isolated from Tinospora cordifolia. Int. Immunopharmacol. 2006, 6:1815-1824.
40. Johnson N., Cunningham A.F., Fooks A.R. The immune response to rabies virus infection and vaccination. Vaccine 2010, 28:3896-3901.
41. + T cells in immunity to viruses. Nat. Rev. Immunol. 2012, 12:136-148.
42. + T cells in viral immunity. J. Exp. Med. 2012, 209:1391-1395.
43. + T cellsubpopulations in retroviral immunity: lessons from the Friend virus mouse model. Retrovirology 2011, 8:76.
44. Kelly G.S. Larch arabinogalactan: clinical relevance of a novel immune-enhancing polysaccharide. Altern. Med. Rev. 1999, 4:96-103.
45. Suarez E.R., Syvitski R., Kralovec J.A., Noseda M.D., Barrow C.J., Ewart H.S., Lumsden M.D., Grindley T.B. Immunostimulatory polysaccharides from Chlorella pyrenoidosa. A new galactofuranan. measurement of molecular weight and molecular weight dispersion by DOSY NMR. Biomacromolecules 2006, 7:2368-2376.
46. Tao Y., Zhang L., Yan F., Wu X. Chain conformation of water-insoluble hyperbranched polysaccharide from fungus. Biomacromolecules 2007, 8:2321-2328.
47. Groman E.V., Enriquez P.M., Jung C., Josephson L. Arabinogalactan for hepatic drug delivery. Bioconjug. Chem. 1994, 5:547-556.